Planning Effective and Affirming Preventive Care Plans Consistent With a Patient’s Current Anatomical Structure
  • CME
  • CE

In this module, a nurse practitioner with expertise in the care of transgender patients provides practical guidance on strategies for developing care plans that are inclusive, patient empowering, and medically accurate by using an organ-based approach and shared decision-making.
person default
Lauren Radziejewski, DNP
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Registered Nurses: 0.75 Nursing contact hours
Pharmacists: 0.75 contact hours (0.075 CEUs)
Released: October 4, 2022 Expiration: October 3, 2023

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Plan effective screening and cancer prevention plans based on an anatomical checklist consistent with the patient’s current anatomical structure.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Merck Sharp & Dohme Corp.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Lauren Radziejewski, DNP

Medical Director
Galileo Health
New York, New York

Lauren Radziejewski, DNP, APRN, has no relevant financial relationships to disclose.

Staff

Rachael M. Andrie, PhD

Scientific Director

Rachael M. Andrie, PhD, has no relevant financial relationships to disclose.
Sara Fagerlie, PhD
Sara Fagerlie, PhD, CHCP, has no relevant financial relationships to disclose.
Timothy A. Quill, PhD

Vice President, Scientific Services

Timothy A. Quill, PhD, has no relevant financial relationships to disclose.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant financial relationships to disclose.
Kristi Kay Orbaugh, MSN, NP, AOCNP

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Kristi Kay Orbaugh, MSN, NP, AOCNP:speaker: AstraZeneca, Bristol-Myers Squibb, DSI, Gilead Sciences, Lilly, MorphoSys, Pfizer, Regeneron, Sanofi.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly, PharmD, BCOP, CHCP, has no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This educational program is intended for all healthcare professionals across multiple disciplines and specialties who care for transgender individuals, including medical oncologists, gynecologists, HIV specialists, primary care physicians, pharmacists, nurses, and nurse practitioners.

Goal

The goal of this education is to advance knowledge, competence, and performance of healthcare professionals to ensure they are providing inclusive care for all patients, including cancer screening and preventive care for transgender individuals.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-234-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 04, 2022, through October 03, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Expert commentary on HRD testing, PARP inhibitor, and quality-of-life studies in rare ovarian cancer from the 2022 ESGO Congress, from Clinical Care Options (CCO)

Prof Isabelle Ray-Coquard, MD, PhD Ignace Vergote, MD, PhD Released: December 2, 2022

On-demand webcast of a live webinar on the urologist’s role in testing and using PARP inhibitors for prostate cancer, from Clinical Care Options (CCO)

person default Stephen Freedland, MD Rana R. McKay, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: November 30, 2022 Expired: November 29, 2023

Enter details about your patient with HER2+ MBC into this online tool from Clinical Care Options (CCO) to see treatment recommendations from 5 experts

Aditya Bardia, MD, MPH Sara Hurvitz, MD, FACP Komal Jhaveri, MD Heather McArthur, MD, MPH Sara Tolaney, MD, MPH Released: November 23, 2022

Clinical Care Options (CCO) presents expert faculty discussing options for the treatment and care of patients with cancer during flu season.

person default Derrick W. Su, MD Released: November 22, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings